about
The role of chemotherapy in advanced solitary fibrous tumors: a retrospective analysisClinical Characteristics and Outcomes for Solitary Fibrous Tumor (SFT): A Single Center Experience.The use of isolated limb infusion in limb threatening extremity sarcomasA tool for discovering drug sensitivity and gene expression associations in cancer cells.Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma.Comprehensive characterization of malignant phyllodes tumor by whole genomic and proteomic analysis: biological implications for targeted therapy opportunities.MRI may be used as a prognostic indicator in patients with extra-abdominal desmoid tumoursRecent progress in the genomics of soft tissue sarcomas.Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trialsMechanisms of resistance to imatinib and sunitinib in gastrointestinal stromal tumor.Cellular immunotherapy for soft tissue sarcomas.Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults.Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.Uterine Adenosarcoma: a Review.Treatment patterns, efficacy and toxicity of regorafenib in gastrointestinal stromal tumour patients.Role of chemotherapy in dedifferentiated liposarcoma of the retroperitoneum: defining the benefit and challenges of the standard.Early Evidence of Cardiotoxicity and Tumor Response in Patients with Sarcomas after High Cumulative Dose Doxorubicin Given as a Continuous Infusion.Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials.Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas.Treatment of Recurrent or Metastatic Uterine Adenosarcoma.The Role of Next-Generation Sequencing in Sarcomas: Evolution From Light Microscope to Molecular Microscope.Progressive and Reversible Conduction Disease With Checkpoint Inhibitors.Chemosaturation with percutaneous hepatic perfusion for unresectable isolated hepatic metastases from sarcoma.Dramatic response to pazopanib in a patient with metastatic malignant granular cell tumor.Targeted next generation sequencing of well-differentiated/dedifferentiated liposarcoma reveals novel gene amplifications and mutations.Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients With BRAF-mutated melanoma and other advanced malignanciesCytokines Produced by Dendritic Cells Administered Intratumorally Correlate with Clinical Outcome in Patients with Diverse CancersMesenchymal Chondrosarcoma: a Review with Emphasis on its Fusion-Driven BiologyThe Importance of Lymphovascular Invasion in Uterine Adenosarcomas: Analysis of Clinical, Prognostic, and Treatment OutcomesOutcome of First-Line Systemic Treatment for Unresectable Conventional, Dedifferentiated, Mesenchymal, and Clear Cell ChondrosarcomaPredictors of survival after resection of primary sarcomas of the chest wall-A large, single-institution seriesHigh-Throughput Architecture for Discovering Combination Cancer TherapeuticsPrognostic factors for uterine adenosarcoma: a reviewPositive Tumor Response to Combined Checkpoint Inhibitors in a Patient With Refractory Alveolar Soft Part Sarcoma: A Case Report
P50
Q33407600-c8f794e7-42bc-9d9a-cac8-bd410125e42dQ35808355-BE75AD96-A547-4945-8C16-8484A270D0EEQ35871652-A7FFA071-3271-41BD-8CCF-E56A893E8848Q36358010-2A41FFE4-B88C-4243-B48A-68578F1E3FDEQ36528916-DC29579E-656C-4D92-BC2E-FCA6A39D679DQ37116937-B3A2C915-9FCF-4C59-A198-D90072B0738DQ37175587-831D9A9D-BAE9-4E36-9CC7-025E588AD4C3Q37182422-BBAA5B6B-9AE6-4AB8-9E2B-10F9F9ADE89AQ37665702-ad42a3fc-435f-a6ec-d09a-3ff642c08472Q37823438-B829C0D3-53E7-43F8-BF37-82F676A42548Q37991779-2CEE9AA6-8FA1-494B-B02F-69932D287D5EQ38678098-9340172A-CA0B-4BBC-932C-D4A14611AC9FQ38699774-3A45AA5D-B4CD-4643-9AC7-E56789501DA0Q38975581-9211BEA2-4427-411E-B06A-D1EFB62EF5E4Q41534349-388BBC24-8B86-46A0-BAC5-407CE4E467ADQ41717674-5E1080FE-829A-4731-8A82-B328D2C30617Q42706690-2CECA271-C6F4-4AD7-89D8-E4ECF9E50B0FQ47096040-732C5234-7978-445A-A6B8-9D704511616BQ47936113-779123A4-A5A3-44EC-9E17-992C76D5DACBQ49870479-EAC9B99D-2931-45E5-BB90-72B2E133984AQ50067454-BA08B189-B8D8-4AC9-B1D0-536059D6D638Q52758556-FF10FB9B-B701-43FB-8D9F-AFC43E9F2142Q53156651-0B55B7B3-65D3-4F3D-9A9B-BC0F994F06EEQ54376301-E552C7B0-0CBB-4921-A594-5120127826CFQ55349624-A8DEAB17-2D2A-4D9A-97B2-07792D918392Q58079189-2ECA45CE-D3F6-4C7C-893A-D52B8CF63638Q62745896-70E3B5DB-189C-4212-AADD-FA4D7BE9DCE0Q88184729-6DCFD52E-DA56-41BA-8653-46DB679E473EQ90464464-59D9EFDF-E789-4002-A442-2FC845D9EDD4Q90785817-D2C5417E-8556-4D2C-8C4C-62C7463A8049Q90954710-9F69A06C-4584-4D58-B7D7-EAD09D1436ADQ91085330-DB850A5B-0189-4758-8D97-2AE31321CA6AQ91250745-30094B5E-2E5E-475A-941A-29F26DB0BB23Q91629150-0DFD6568-AD31-4759-B6D3-C1979D9397E5
P50
description
American oncologist
@en
US-amerikanischer Onkologe
@de
wetenschapper
@nl
name
Anthony P. Conley
@de
Anthony P. Conley
@en
Anthony P. Conley
@fr
Anthony P. Conley
@nl
type
label
Anthony P. Conley
@de
Anthony P. Conley
@en
Anthony P. Conley
@fr
Anthony P. Conley
@nl
prefLabel
Anthony P. Conley
@de
Anthony P. Conley
@en
Anthony P. Conley
@fr
Anthony P. Conley
@nl
P108
P227
P106
P108
P21
P227
1143169298
P31
P496
0000-0002-6232-1163